Journal of Comparative Effectiveness Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol
Discussion: The findings may help to quantify existing inequities in clinical trial participation that may be addressed through optimizing enrollment strategies for future PAD trials. Systematic review registration: PROSPERO (CRD42022378304).PMID:37947288 | DOI:10.57264/cer-2023-0048 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - November 10, 2023 Category: General Medicine Authors: Chandler Long Abimbola O Williams Caroline M Jacobsen Alysha M McGovern Liesl M Hargens Sue Duval Michael R Jaff Source Type: research

Access in all areas? A round up of developments in market access and health technology assessment: part 2
J Comp Eff Res. 2023 Nov 2:e230162. doi: 10.57264/cer-2023-0162. Online ahead of print.ABSTRACTIn this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on. We also cover the consequences of price controls and rigid value assessment in Germany which have led to the withdrawal of a number of medicines. It will be important to see how the IRA balances cost-saving with holistic value assessment, incentives for innovation and patient access to...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Alice Beattie Catrin Treharne Silvy Mardiguian Sreeram V Ramagopalan Source Type: research

Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems
Conclusion: This study uses reengineering and design techniques to introduce priority strategies to allow more efficient and patient-centered radiotherapy.PMID:37916706 | DOI:10.57264/cer-2023-0023 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Ana Paula Beck da Silva Etges Luciana Rodrigues de Lara Stella Lisboa Sapper Ana Von Frankenberg Berger Melissa Streck Laise Zardo Armani Linhares Marina Nassif Ang élica Zanotto Marta Nassif Pereira Lima Rafael Vargas Carisi Anne Polanczyk Source Type: research

Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
J Comp Eff Res. 2023 Nov 2:e230073. doi: 10.57264/cer-2023-0073. Online ahead of print.ABSTRACTA decision analytic model was constructed to assess the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost-effectiveness than the conventional therapies. Survival outcomes, quality of life of progression-free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost-effectiveness of O-B-O. The cost-ef...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Jun Ma Donglu Zhao Bihong Zhen Yan Xia Qianyi Gong Wendong Chen Source Type: research

Access in all areas? A round up of developments in market access and health technology assessment: part 2
J Comp Eff Res. 2023 Nov 2:e230162. doi: 10.57264/cer-2023-0162. Online ahead of print.ABSTRACTIn this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on. We also cover the consequences of price controls and rigid value assessment in Germany which have led to the withdrawal of a number of medicines. It will be important to see how the IRA balances cost-saving with holistic value assessment, incentives for innovation and patient access to...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Alice Beattie Catrin Treharne Silvy Mardiguian Sreeram V Ramagopalan Source Type: research

Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems
Conclusion: This study uses reengineering and design techniques to introduce priority strategies to allow more efficient and patient-centered radiotherapy.PMID:37916706 | DOI:10.57264/cer-2023-0023 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Ana Paula Beck da Silva Etges Luciana Rodrigues de Lara Stella Lisboa Sapper Ana Von Frankenberg Berger Melissa Streck Laise Zardo Armani Linhares Marina Nassif Ang élica Zanotto Marta Nassif Pereira Lima Rafael Vargas Carisi Anne Polanczyk Source Type: research

Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
J Comp Eff Res. 2023 Nov 2:e230073. doi: 10.57264/cer-2023-0073. Online ahead of print.ABSTRACTA decision analytic model was constructed to assess the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost-effectiveness than the conventional therapies. Survival outcomes, quality of life of progression-free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost-effectiveness of O-B-O. The cost-ef...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Jun Ma Donglu Zhao Bihong Zhen Yan Xia Qianyi Gong Wendong Chen Source Type: research

Access in all areas? A round up of developments in market access and health technology assessment: part 2
J Comp Eff Res. 2023 Nov 2:e230162. doi: 10.57264/cer-2023-0162. Online ahead of print.ABSTRACTIn this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on. We also cover the consequences of price controls and rigid value assessment in Germany which have led to the withdrawal of a number of medicines. It will be important to see how the IRA balances cost-saving with holistic value assessment, incentives for innovation and patient access to...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Alice Beattie Catrin Treharne Silvy Mardiguian Sreeram V Ramagopalan Source Type: research

Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems
Conclusion: This study uses reengineering and design techniques to introduce priority strategies to allow more efficient and patient-centered radiotherapy.PMID:37916706 | DOI:10.57264/cer-2023-0023 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Ana Paula Beck da Silva Etges Luciana Rodrigues de Lara Stella Lisboa Sapper Ana Von Frankenberg Berger Melissa Streck Laise Zardo Armani Linhares Marina Nassif Ang élica Zanotto Marta Nassif Pereira Lima Rafael Vargas Carisi Anne Polanczyk Source Type: research

Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
J Comp Eff Res. 2023 Nov 2:e230073. doi: 10.57264/cer-2023-0073. Online ahead of print.ABSTRACTA decision analytic model was constructed to assess the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost-effectiveness than the conventional therapies. Survival outcomes, quality of life of progression-free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost-effectiveness of O-B-O. The cost-ef...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Jun Ma Donglu Zhao Bihong Zhen Yan Xia Qianyi Gong Wendong Chen Source Type: research

Access in all areas? A round up of developments in market access and health technology assessment: part 2
J Comp Eff Res. 2023 Nov 2:e230162. doi: 10.57264/cer-2023-0162. Online ahead of print.ABSTRACTIn this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on. We also cover the consequences of price controls and rigid value assessment in Germany which have led to the withdrawal of a number of medicines. It will be important to see how the IRA balances cost-saving with holistic value assessment, incentives for innovation and patient access to...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Alice Beattie Catrin Treharne Silvy Mardiguian Sreeram V Ramagopalan Source Type: research

Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems
Conclusion: This study uses reengineering and design techniques to introduce priority strategies to allow more efficient and patient-centered radiotherapy.PMID:37916706 | DOI:10.57264/cer-2023-0023 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Ana Paula Beck da Silva Etges Luciana Rodrigues de Lara Stella Lisboa Sapper Ana Von Frankenberg Berger Melissa Streck Laise Zardo Armani Linhares Marina Nassif Ang élica Zanotto Marta Nassif Pereira Lima Rafael Vargas Carisi Anne Polanczyk Source Type: research